A retrospective study including 41 patients with SCLC who received anti-PD-1/PD-L1 antibodies as second- or later-line treatment evaluated NLR and PLR at baseline and 6 weeks post-treatment. This evidence concerns the gene CD274 and small cell lung carcinoma.